title: On the activation of human leuserpin-2, a thrombin inhibitor, by glycosaminoglycans.
abstract: Human leuserpin-2 (hLS2) cDNA variants generated by site-directed mutagenesis were expressed in a transient COS cell system. Functional analysis of the mutants revealed two regions in the NH2-terminal half of hLS2 which are essential for glycosaminoglycan-enhanced thrombin inhibition by hLS2. One of these regions, which encompasses a dimeric structure enriched in basic amino acids, is required for both glycosaminoglycan binding and glycosaminoglycan-mediated acceleration of thrombin inhibition. Deletion of another dimeric region, which spans a sequence with a high negative charge density, resulted in a strong reduction in the glycosaminoglycan-enhanced activity of hLS2. This polyanionic region displays structural and functional similarities to the COOH-terminal end of hirudin, another potent thrombin inhibitor, indicating that both inhibitors may have a common binding site on thrombin. Based on our observations we propose a model for the activation of hLS2 by glycosaminoglycans. The key feature of this model is the suggestion that the glycosaminoglycan-enhanced reaction between hLS2 and thrombin is mediated by at least two regions of contact, involving both the reactive center region and the acidic domain of hLS2. Binding of glycosaminoglycans to hLS2 is suggested to result first in the release of the acidic region from intramolecular interactions. Then, amino acid sequences in thrombin are proposed to interact with the acidic dimer of hLS2.
authors.affiliation: Hoechst AG, Frankfurt, Federal Republic of Germany.
authors.forename: H
authors.initials: H
authors.lastname: Ragg
authors.forename: T
authors.initials: T
authors.lastname: Ulshöfer
authors.forename: J
authors.initials: J
authors.lastname: Gerewitz
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D001665:Binding Sites; D002460:Cell Line; D002872:Chromosome Deletion; D003871:Dermatan Sulfate / Q000494:pharmacology; D014644:Genetic Variation; D006025:Glycosaminoglycans / Q000494:pharmacology*; D006493:Heparin / Q000494:pharmacology; D015844:Heparin Cofactor II / Q000235:genetics / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D046911:Macromolecular Substances; D008961:Models, Structural; D008969:Molecular Sequence Data; D009154:Mutation; D011487:Protein Conformation; D013917:Thrombin / Q000037:antagonists & inhibitors; D014162:Transfection
chemical_list: D006025:Glycosaminoglycans; D046911:Macromolecular Substances; C047932:SERPIND1 protein, human; D003871:Dermatan Sulfate; D015844:Heparin Cofactor II; D006493:Heparin; D013917:Thrombin